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Introduction
Mifepristone is a synthetic steroid that acts as a competi-
tive blocker of both progesterone and cortisone receptors
[1]. Misoprostol is a prostaglandin analog used to
prevent gastric ulcers induced by nonsteroidal anti-
inflammatory drugs [2]. The mifepristone/misoprostol
combination (MMC) is an effective method to termi-
nate early pregnancy [1–3], because mifepristone
increases myometrial sensitivity to prostaglandin in
pregnant women [4]. Taking oral misoprostol 36–48
hours after mifepristone is the most common regimen
used to terminate a pregnancy of up to 49 days’ gesta-
tion [1]. With this regimen, complete abortion rates of
87% [5] and 96% have been reported [6]. Mild vaginal
spotting or bleeding on day 14 after administering
MMC may suggest the presence of products of con-
ception, which are prone to infection. Our study, per-
SUMMARY
Objective: The oral mifepristone/misoprostol combination (MMC) is safe for medical abortion in early
pregnancy. The abortion status in MMC-treated pregnancies at Taipei Medical University–Wan Fang Medical
Center was determined by ultrasonography, serum `-human chorionic gonadotropin (`-HCG), and
histopathology.
Methods: All women at less than 49 days since the last menstruation who asked for legal abortion were evaluated
by ultrasonography. They then received 600 mg of oral mifepristone followed 48 hours later by 600 +g of
misoprostol. Women who had vaginal spotting or bleeding after 14 days were included in this study and
underwent transvaginal ultrasonography, serum `-HCG measurement and vacuum aspiration or therapeutic
dilatation and curettage (D&C) on day 14. Specimens were identified by histopathology. Abortion status was
determined from linear regression of serum `-HCG and endometrial thickness.
Results: Of 35 women who underwent vacuum aspiration or therapeutic D&C, histopathology showed that
20 had decidual tissue and 15 had gestational tissue. Logistic regression showed that the distance measurement
to the logistic regression line differed significantly between complete and incomplete abortion (p < 0.05).
Conclusion: In this study, serum `-HCG assays in addition to ultrasonographic evaluation helped to discriminate
abortion status after oral MMC. [Taiwanese J Obstet Gynecol 2006;45(1):48–52]
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formed at the Taipei Medical University–Wan Fang
Medical Center (TMU-WFMC), Taipei, Taiwan, was
intended to predict complete abortion status after
administering MMC, using serum `-human chorionic
gonadotropin (`-HCG) and ultrasonographic measure-
ment of endometrial thickness.
Methods
We studied patients who requested legal termination
of pregnancy at TMU-WFMC from October 1, 2004, to
January 30, 2005. We excluded heavy cigarette smokers
(> 10/day), all patients with cardiovascular disease,
asthma, possible ectopic pregnancy, and hematologic
disorders, and patients with ultrasonographic proof
of pregnancy of more than 49 days’ gestation (crown–
rump length or gestational sac). Written informed
consent was obtained from each patient before being
enrolled in the study.
Patients were given 600 mg of oral mifepristone
(Apano; Lotus Pharmaceutical Co Ltd, Taipei, Taiwan)
followed by 600 +g of misoprostol (Cytotec; Searle,
Morpeth, Northumberland, UK) 48 hours later. A 24-
hour on-call telephone number was provided to ans-
wer any questions. All patients were instructed to re-
turn for a post-treatment ultrasound examination on
day 14 after taking the first pills. We enrolled patients
who complained of vaginal spotting or bleeding and
evaluated endometrial thickness and serum `-HCG
on day 14. All enrolled patients underwent vacuum
aspiration or therapeutic dilatation and curettage
(D&C).
Enrolled patients underwent ultrasonic examin-
ation with real-time ultrasound equipment (Image
Point; Hewlett Packard, Andover, MA, USA) and using
a 5–10-MHz transducer to measure endometrial thick-
ness by identifying the long axis (anterioposterior di-
mension or “height”) of the uterus, including both
opposing layers of the endometrium [7]. All specimens
removed by vacuum aspiration or therapeutic D&C
were sent for pathologic examination. Patients were
considered to have an incomplete abortion if the patho-
logic findings of the specimens revealed trophoblasts
or chorionic villae.
Statistical analyses
We used logistic regression to correlate patients’
serum ` -HCG and endometrial thickness with the abor-
tion status, and to estimate coefficients of regression to
discriminate whether the pregnancy was successful.
We used the `-HCG and endometrial thickness va-
lues as risk factors for gestational age, and built logistic
models with different risk factors for improved discrimi-
nation between complete and incomplete abortion.
Results
In this study, 35 patients with a mean age of 31.7 (
3.6 years and a mean gestational age of 5.3 ( 1.1 weeks
had an intrauterine pregnancy visible on transvagi-
nal ultrasonography. Of these women, 31.4% were
nulliparous and 68.6% multiparous.
Figure 1 shows serum `-HCG and endometriotic
thickness against pregnancy outcome for all 35 pa-
tients. Through logistic regression, we calculated the
distance to the logistic regression line relative to the
probability of success (Table 1). We defined the odds
ratio of being a “case” at follow-up for those who were
a “case” at the first examination compared to those who
were a “non-case” at baseline. The estimated coefficients
showed that `HCG was significantly associated with
Table 1. Results of fitting logistic regression model
Parameter Estimated coefficient Standard error Pr > Z–
Intercept –4.9377260 1.782502 0.005604
Distance . 0.9403954 0.451322 0.037192
Pr = probability; Z = normal distributed random variable.
100,000
10,000
1,000
100
10
1
`<
H
C
G
 (
m
lU
/m
l)
5 10 15 20 25
Endometrial thickness (mm)
Figure 1. Patients with complete ( ) and incomplete ( )
abortion. `-HCG = `-human chorionic gonadotropin.
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the presence of gestational tissue, and logistic regression
showed that the measurement result was significantly
different between complete and incomplete abortion
(p < 0.05).
We performed discriminant analysis to determine
whether the abortion was complete (Table 2). With
this analysis, we classified the patient correctly in
97.14% of patients. Using logistic regression, the in-
fluence of different variables on the complication was
studied. Therefore, we were assured that the discrimin-
ant method, including endometrial thickness and `-
HCG, was better than that determined simply by serum
`-HCG concentration.
Discussion
MMC used according to the manufacturer’s protocol
[8] is an alternative to vacuum aspiration to terminate
an early pregnancy, after all possible contraindications
are considered. Patients who undergo vacuum aspira-
tion are more likely have heavier vaginal bleeding, in-
fection, and mechanical trauma than those who receive
MMC [2]. Based on the results of this study, we suggest
the use of ultrasonography and serum `-HCG assays
to help prompt diagnosis and management [9] if pa-
tients have an uncertain outcome or suspected ectopic
pregnancy.
Rulin et al found that when the endometrial stripe
is about 10 mm wide, products of conception are un-
likely to be detected [10]. In other studies, an endo-
metrial stripe of 8 mm or less was used for diagnosis
of complete abortion [11].
Honkanen et al reported that by day 14, serum
HCG concentrations have declined by 99.4 ( 10% and
that the route of medication administration (oral or
vaginal) has no effect on the kinetics of serum `-HCG
in patients treated for medical abortion [12]. Another
study reported that failed or incomplete abortion oc-
curs when pregnancy tests with sensitivities of at
least 1,000 mIU/mL are positive within 2 weeks after
surgical abortion[13].
In France, MMC is often used to terminate a preg-
nancy before 50 days of amenorrhea, which is calculated
from the first day of the last menstrual period, with a
complete abortion rate of about 95% [8]. In a previous
study, we reported that most Taiwanese patients who
asked for legal abortion before 49 days from the last
menstruation were evaluated ultrasonographically.
The study showed that the complete abortion rate was
only 78.5% [14]. This discrepant finding suggests
that the optimal MMC regimen in Taiwan needs to be
established [15].
Some studies have revealed that oral misoprostol is
less effective in causing abortion and produces more
side effects than vaginal misoprostol [3]. Oral miso-
prostol is licensed to prevent gastric ulcers induced by
nonsteroidal anti-inflammatory drugs. The misoprostol
tablet is inexpensive, stable, and effective for medi-
cal abortion [2], but it was not developed and manu-
factured for vaginal use. We chose to use 600 +g of oral
misoprostol in MMC because the vaginal route is
uncomfortable and painful for the patient [16]. Studies
to develop a drug that can be administered by different
routes are also needed. Thus, more studies on the best
MMC protocol for the legal termination of early preg-
nancy are needed in different populations. Based on the
results of our study, we suggest a new protocol for most
Taiwanese women (Figure 2).
Previous studies on patient satisfaction with medi-
cal abortion revealed two disadvantages: the need for
many office visits and the prolonged time of waiting
until the abortion is over [17,18]. Based on the findings
of this study, mild vaginal spotting or bleeding on day
14 after administration of MMC does not guarantee
the absence of products of conception, which are at
high risk of infection, and serum ` -HCG assays can help
ultrasonographic evaluation of abortion status after
oral MMC.
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